Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Dec;9(12):103968.
doi: 10.1016/j.esmoop.2024.103968. Epub 2024 Nov 27.

Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study

N Girard  1 , F Guisier  2 , A Swalduz  3 , S Van Hulst  4 , E Pichon  5 , P Lavaud  6 , L Greillier  7 , A Tiotiu  8 , A Madroszyk  9 , O Bylicki  10 , A Canellas  11 , L Belmont  12 , M Zysman  13 , P-A Hauss  14 , B Godbert  15 , C Audigier-Valette  16 , C Lebreton  17 , F Morin  17 , V Westeel  18
Affiliations
Multicenter Study

Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study

N Girard et al. ESMO Open. 2024 Dec.

Abstract

Background: Small-cell lung cancer (SCLC) is a highly aggressive type of lung cancer. Lurbinectedin is recommended as second-/third-line treatment for advanced, previously treated SCLC.

Materials and methods: LURBICLIN is a nationwide, non-interventional, retrospective chart review study, based on the cohort of consecutive patients enrolled in the named patient use for lurbinectedin in France.

Results: A total of 312 patients were included. Lurbinectedin was delivered as second-line therapy in 138 (44%) patients. Grade 3-4 treatment-related adverse events were observed in 28 (9%) and 15 (5%) patients, respectively. Objective response rate (ORR) to lurbinectedin was 22% in the intention-to-treat population. After a median follow-up of 20.8 months, median progression-free survival (PFS) was 1.9 months [95% confidence interval (CI) 1.8-2.0 months]. At multivariate analysis, chemotherapy-free interval (CTFI) ≥ 90 days was an independent predictor of higher PFS [hazard ratio (HR) = 0.64, 95% CI 0.50-0.84, P < 0.0001]. The median overall survival (OS) was 4.7 months (95% CI 4.0-5.4 months). At multivariate analysis, performance status < 2 and CTFI ≥ 90 days were independent predictors of higher OS (HR = 0.71, 95% CI 0.53-0.95, P = 0.03; and HR = 0.58, 95% CI 0.44-0.76, P < 0.0001, respectively). Overall, 147 (47%) patients had initiated subsequent systemic treatments.

Conclusions: LURBICLIN confirms the activity of lurbinectedin in patients with SCLC with a manageable safety profile. Lurbinectedin monotherapy provides an alternative option for SCLC patients.

Keywords: chemotherapy; compassionate use trials; immunotherapy; lurbinectedin; small-cell lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Overall survival and (B) progression-free survival in 312 patients who received lurbinectedin. (C) Overall survival and (D) progression-free survival according to chemotherapy-free interval. Red is CTFI > 90 days. CI, confidence interval; CTFI, chemotherapy-free interval; OS, overall survival; PFS, progression-free survival.
See this image and copyright information in PMC

References

    1. Gazdar A.F., Bunn P.A., Minna J.D. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:725–737. - PubMed
    1. Dingemans A.C., Früh M., Ardizzoni A., et al. ESMO Guidelines Committee Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:839–853. - PMC - PubMed
    1. National Comprehensive Cancer Network Small-cell lung cancer. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf Available at.
    1. Trigo J., Subbiah V., Besse B., et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645–654. - PubMed
    1. Aix S.P., Ciuleanu T.E., Navarro A., et al. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet Respir Med. 2023;11:74–86. - PubMed

Publication types

MeSH terms